drugset / Trial / NCT04026165

Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease

NCT04026165

Phase 2 Completed 384 enrolled Gilead Sciences
RandomizedSequentialDouble-blindTreatment

Summary

The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).

Timeline

Start
2019-07-24
Primary completion
2021-09-03
Completion
2021-09-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Selonsertib Small molecule 18 mg Oral